GlassScriptPhysician profile
Justin C Moser
NPI 1891133989
$54,603.89
in general payments reported to CMS, 2019-2025
18 companies · $21K in 2025
The $21K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $2,338 · 2021: $1,513 · 2022: $5,483 · 2023: $20K · 2024: $4,394 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $31K · Honoraria: $5,650 · Travel and Lodging: $4,839 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,160 · Food and Beverage: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $31,182.00 |
| Honoraria | $5,650.00 |
| Travel and Lodging | $4,838.55 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,160.00 |
| Food and Beverage | $1,440.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $15,077.09 | 2020-2024 | Opdivo |
| Immunocore Limited | $11,488.33 | 2022-2025 | Kimmtrak |
| Sun Pharmaceutical Industries INC. | $9,194.65 | 2025 | |
| Incyte Corporation | $8,416.36 | 2023 | |
| Iovance Biotherapeutics, INC. | $6,163.45 | 2024-2025 | Amtagvi |
| Array Biopharma INC | $2,300.27 | 2024 | Braftovi, Mektovi |
| Caris Mpi, INC. | $1,689.83 | 2025 | Mi Cancer Seek |
| Genzyme Corporation | $188.64 | 2023 | |
| Trisalus Life Sciences, INC. | $44.72 | 2023 | Trinav Infusion System |
| Adaptimmune LLC | $40.55 | 2025 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Moser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.